Abstract Details

Title Clinical and Neuroimaging Correlates of Cognitive Impairment in Parkinson’s Disease

Topic Movement Disorders

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-021

Objective

Define clinical correlates of cognitive impairment in Parkinson’s disease (PD) patients of low education level and identify structural brain predictors of cognitive performance.

Background Cognitive assessments for PD have limitations in evaluating populations of lower education levels or with mild cognitive impairments. Symptom severity and diagnoses are aided by clinical scales that demand a minimum level of cognition and literacy. Interventions, i.e. DBS, and clinical trials, generally require prior cognitive evaluation to ensure patient eligibility and comprehension. These scales are subject to flooring effects that exclude groups with cognitive deficits. If specific brain region atrophy correlates to clinical assessments, this could be an alternative option to the intervention vetting process.

Design/Methods Retrospective analysis of MRI-imaging and clinical data from 41 PD individuals (15F/25M, median age 65 years, education level median 6.5 years, and illness duration median 10 years). Group comparisons for (control vs. PD) and (PD cognitive impairment vs. PD without cognitive impairment) were assessed by conventional statistics (Student’s t-test, Mann-Whitney test). Correlation analysis (Pearson, Spearman) was run to investigate the association between Mattis Dementia Rating Scale (MDRS) scores and neuroimaging data. Clinical variables (age, gender, Unified Parkinson’s Disease Rating Scale (UPDRS) total score, and volumetric/cortical thickness measurements analyzed in a logistic regression model as potential predictors of cognitive impairment in PD.

Results Cortical thickness and volume differences between 22 brain regions of interest (ROI) in both hemispheres for (PD vs healthy controls) were observed. A low (≤130) MDRS-total score, reflective of lower cognitive performance, correlated with the cortical thickness (LH/RH-insula, RH-entorhinal cortex, LH-pars orbitalis, LH-supramarginal gyrus) and RH-fusiform gyrus volume. Additionally, the UPDRS-total score was the only significant predictor of cognitive impairment in the regression analyses.

Conclusions The UPDRS-total score, a surrogate measure of total PD disease burden, was the most consistent clinical correlate of cognitive impairment in PD.

Authors/Disclosures
Frank Ramirez PRESENTER	Mr. Ramirez has nothing to disclose.
Thiago Macedo E Cordeiro	The institution of Thiago Macedo E Cordeiro has received research support from the HDSA.
Erin Furr-Stimming, MD, FAAN (University of Texas Health Science Center-Houston)	Dr. Furr-Stimming has received personal compensation for serving as an employee of Help4HD International. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedPage. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atalanta Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SkyHawk Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atalanta Therapeutics. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine Bioscienes. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. The institution of Dr. Furr-Stimming has received research support from HDSA. The institution of Dr. Furr-Stimming has received research support from Prilennia. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has a non-compensated relationship as a Committee member with AAN UES Committee that is relevant to AAN interests or activities.
Natalia Pessoa Rocha	Natalia Pessoa Rocha has nothing to disclose.

��ɫ��

��ɫ��